Caldiamide sodium anhydrous

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 412235

CAS#: 131410-50-9 (anhydrous)

Description: Caldiamide sodium anhydrous is a biochemical

Chemical Structure

Caldiamide sodium anhydrous
CAS# 131410-50-9 (anhydrous)

Theoretical Analysis

MedKoo Cat#: 412235
Name: Caldiamide sodium anhydrous
CAS#: 131410-50-9 (anhydrous)
Chemical Formula: C16H26CaN5NaO8
Exact Mass: 479.1305
Molecular Weight:
Elemental Analysis: C, 40.08; H, 5.47; Ca, 8.36; N, 14.61; Na, 4.79; O, 26.69

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 122760-91-2 (salt)   128326-81-8 (free base)   131410-50-9 (anhydrous)  

Synonym: Caldiamide sodium anhydrous; CCRIS6697; CCRIS-6697; CCRIS 6697

IUPAC/Chemical Name: calcium sodium 5,8-bis(carboxylatomethyl)-11-(2-(methylamino)-2-oxoethyl)-3-oxo-2,5,8,11-tetraazatridecan-13-oate


InChi Code: InChI=1S/C16H29N5O8.Ca.Na/c1-17-12(22)7-20(10-15(26)27)5-3-19(9-14(24)25)4-6-21(11-16(28)29)8-13(23)18-2;;/h3-11H2,1-2H3,(H,17,22)(H,18,23)(H,24,25)(H,26,27)(H,28,29);;/q;+2;+1/p-3

SMILES Code: CNC(CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(NC)=O)CC([O-])=O)=O.[Na+].[Ca+2]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Yip WL, Soosainather TC, Dyrstad K, Sande SA. Classification of structurally related commercial contrast media by near infrared spectroscopy. J Pharm Biomed Anal. 2014 Mar;90:148-60. doi: 10.1016/j.jpba.2013.11.033. Epub 2013 Dec 7. PMID: 24374816.

2: Fretellier N, Idée JM, Dencausse A, Karroum O, Guerret S, Poveda N, Jestin G, Factor C, Raynal I, Zamia P, Port M, Corot C. Comparative in vivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study. Invest Radiol. 2011 May;46(5):292-300. doi: 10.1097/RLI.0b013e3182056ccf. PMID: 21263333.

3: Pietsch H, Raschke M, Ellinger-Ziegelbauer H, Jost G, Walter J, Frenzel T, Lenhard D, Hütter J, Sieber MA. The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats. Invest Radiol. 2011 Jan;46(1):48-56. doi: 10.1097/RLI.0b013e3181efd49a. PMID: 20938346.

4: Fretellier N, Idée JM, Guerret S, Hollenbeck C, Hartmann D, González W, Robic C, Port M, Corot C. Clinical, biological, and skin histopathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis. Invest Radiol. 2011 Feb;46(2):85-93. doi: 10.1097/RLI.0b013e3181f54044. PMID: 20938344.

5: Grant D, Johnsen H, Juelsrud A, Løvhaug D. Effects of gadolinium contrast agents in naïve and nephrectomized rats: relevance to nephrogenic systemic fibrosis. Acta Radiol. 2009 Mar;50(2):156-69. doi: 10.1080/02841850802637808. PMID: 19160079.

6: Sieber MA, Pietsch H, Walter J, Haider W, Frenzel T, Weinmann HJ. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol. 2008 Jan;43(1):65-75. doi: 10.1097/RLI.0b013e31815e6277. PMID: 18097279.

7: Okazaki O, Kurata T, Yoshioka N, Hakusui H. Pharmacokinetics and stability of caldiamide sodium in rats. Arzneimittelforschung. 1996 Jan;46(1):79-83. PMID: 8821523.

8: Lai JJ, Jamieson GC. Determination of dysprosium in monkey serum by inductively-coupled plasma atomic emission spectrometry (ICP-AES) after the administration of Sprodiamide Injection, a new contrast medium for magnetic resonance imaging. J Pharm Biomed Anal. 1993 Nov-Dec;11(11-12):1129-34. doi: 10.1016/0731-7085(93)80093-g. PMID: 8123724.

9: Carvlin MJ, Rajan SS, Rosa L, Muraki AS, Francisco J, Rocklage SM. Efficacy of nonionic low-osmolar gadodiamide injection in animals with intracranial mass lesions. J Magn Reson Imaging. 1992 Jan-Feb;2(1):19-24. doi: 10.1002/jmri.1880020104. PMID: 1623277.